Open access
Real‐world implementation of lecanemab in Alzheimer's disease: A Japanese cohort
S. Shimohama
S. Bun
Ryo Shikimoto
H. Tomioka
Toshiki Takayama
Yuko Mimura
Hiroki Sasaguri
Koji Sekiguchi
Yoshinori Nishimoto
Y. Iwabuchi
H. Tabuchi
Jin Nakahara
M. Mimura
Daisuke Ito
Medicine
Abstract
Real‐world evidence for lecanemab remains limited, particularly among Asian populations. We evaluated the feasibility, safety, biomarker profiles, and short‐term clinical outcomes of lecanemab in practice in Japan.